September 22, 2006 -- Merck won European approval for Gardasil, the cervical cancer vaccine; Epix reported its anxiety drug candidate failed a Phase III trial; Oscient got an approvable letter for Factive as a therapy for community-acquired pneumonia; Schering-Plough received a recommendation from European regulators for Noxafil; Alcon received FDA approval for Travatan Z, a therapy that relieves intraocular pressure; Warner Chilcott priced 70.6 million shares at $15, raising $1.06 billion; BioVex will seek to place 3.4 million shares in an $11-$13 range; Achillion Pharma will offer 4.5 million shares in a $14-$16 range; Kos Pharma said Icatibant produced mixed results against hereditary angioedema; Amylin and Lilly received a recommendation in Europe for Byetta; and OXiGENE said its vascular disrupting agent was effective against cancer in lab tests. The Centient Biotech 200™ fell 15.5 points to 3228.84, a loss of .41%. More details...
